Overview

Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With Neuroblastoma

Status:
Withdrawn
Trial end date:
2014-01-16
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the best dose of imetelstat when given alone for patients with neuroblastoma and also when given in combination with 13-cis-retinoic acid.
Phase:
Phase 1
Details
Lead Sponsor:
NCIC Clinical Trials Group
Collaborator:
Geron Corporation
Treatments:
Imetelstat
Isotretinoin
Motesanib diphosphate
Niacinamide
Tretinoin